Artículos por temáticas

Mitochondrial microRNAs: Key Drivers in Unraveling Neurodegenerative Diseases

Yashooa RK, Duranti E, Conconi D, Lavitrano M, Mustafa SA, Villa C.

Int J Mol Sci. 2025 Jan 13;26(2):626. doi: 10.3390/ijms26020626.

The Crucial Role of the Blood-Brain Barrier in Neurodegenerative Diseases: Mechanisms of Disruption and Therapeutic Implications

Kim S, Jung UJ, Kim SR.

J Clin Med. 2025 Jan 9;14(2):386. doi: 10.3390/jcm14020386.

Mechanisms of Copper-Induced Autophagy and Links with Human Diseases

Fu Y, Zeng S, Wang Z, Huang H, Zhao X, Li M.

Pharmaceuticals (Basel). 2025 Jan 15;18(1):99. doi: 10.3390/ph18010099.

Expanding Horizons in Parkinson's Disease: Towards Integrated Care and Comprehensive Research

Rodríguez-Molinero A.

J Clin Med. 2025 Jan 9;14(2):385. doi: 10.3390/jcm14020385.

Biomechanics Parameters of Gait Analysis to Characterize Parkinson's Disease: A Scoping Review

Russo M, Amboni M, Pisani N, Volzone A, Calderone D, Barone P, Amato F, Ricciardi C, Romano M.

Sensors (Basel). 2025 Jan 9;25(2):338. doi: 10.3390/s25020338.

Are glucagon-like peptide-1 (GLP-1) receptor agonists useful in treating Parkinson's disease (PD)? Does the clinical trial with lixisenatide add anything?

Doggrell SA.

Expert Opin Investig Drugs. 2025 Jan 29:1-5. doi: 10.1080/13543784.2025.2459409. Online ahead of print.

Impact of the Ketogenic Diet on Neurological Diseases: A Review

Rubio C, López-Landa A, Romo-Parra H, Rubio-Osornio M.

Life (Basel). 2025 Jan 9;15(1):71. doi: 10.3390/life15010071.

Neurogenic Orthostatic Hypotension in Parkinson Disease-A Narrative Review of Diagnosis and Management

Grosu C, Noea O, Maștaleru A, Ignat EB, Leon MM.

J Clin Med. 2025 Jan 19;14(2):630. doi: 10.3390/jcm14020630.

How to Manage an Individual Living with Parkinson's Disease Who Acutely Cannot Swallow

Teranaka M, Teranaka W, Jones HT.

Br J Hosp Med (Lond). 2025 Jan 24;86(1):1-10. doi: 10.12968/hmed.2024.0518. Epub 2025 Jan 17.

Large-scale genetic characterization of Parkinson's disease in the African and African admixed populations

Akçimen F, Paquette K, Crea PW, Saffie-Awad P, Achoru C, Taiwo F, Ozomma S, Onwuegbuzie G, Khani M, Grant S, Owolabi L, Okereke C, Oshinaike O, Iwuozo E, Lee PS, Oyakhire S, Osemwegie N, Daida K, Abub

medRxiv [Preprint]. 2025 Jan 20:2025.01.14.25320205. doi: 10.1101/2025.01.14.25320205.

Preclinical Evaluation of [ (18) F]P4B-2412 as Phosphodiesterase 4B Radioligand for Positron Emission Tomography Imaging

Song Z, Li Y, Feng S, Chen J, Zhou X, Zhang Z, Sun Z, Rong J, Zhao C, Chaudhary A, Patel JS, Gao Y, Collier TL, Ran C, Haider A, Yuan H, Liang SH.

bioRxiv [Preprint]. 2025 Jan 16:2025.01.16.633384. doi: 10.1101/2025.01.16.633384.

Irregular sleep-wake rhythm disorder: From the pathophysiologic perspective to the treatment

Videnovic A, Cai A.

Handb Clin Neurol. 2025;206:71-87. doi: 10.1016/B978-0-323-90918-1.00006-X.

Evolving Landscape of Parkinson's Disease Research: Challenges and Perspectives

Tenchov R, Sasso JM, Zhou QA.

ACS Omega. 2025 Jan 8;10(2):1864-1892. doi: 10.1021/acsomega.4c09114. eCollection 2025 Jan 21.

A Comparison of In-Person and Telehealth Treatment Modalities using the SpeechVive Device

Covert R, Snyder S, Lambert A, Spremulli M, Blandford B, Dwenger K, Malandraki G, McDonough M, Brosseau-Lapre F, Huber JE.

medRxiv [Preprint]. 2025 Jan 17:2025.01.16.25320611. doi: 10.1101/2025.01.16.25320611.

Sleep and circadian dysfunction in Parkinson disease: New perspective and opportunities for treatment

Shen Y, Liu CF.

Handb Clin Neurol. 2025;206:193-209. doi: 10.1016/B978-0-323-90918-1.00002-2.